BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 2, 2007
View Archived Issues
Study reveals advantages of insulin VIAject over insulin lispro, regular insulin
Read More
Tetrodotoxin relieves severe cancer-related pain
Read More
UK-500,001 ineffective in asthma, COPD studies
Read More
Inhibition of MarA virulence factor increases survival in Pseudomonas aeruginosa pneumonia model
Read More
Incyte provides update on positive proof-of-concept results from pipeline
Read More
NPS licenses rights to Gattex outside of North America to Nycomed
Read More
CombinatoRx begins CRx-102 phase IIb clinical study in knee osteoarthritis
Read More
Asentar enters phase II trial in pancreatic cancer and is in ongoing phase III AIPC trial
Read More
Series A financing raises USD 20 million for Sequel
Read More
OctoPlus acquires worldwide rights to Theratechnologies' GLP-1 analogues
Read More
Positive results for SIGA's preclinical trials of ST-246 for smallpox
Read More
NexGenix signs worldwide Hsp90 inhibitors agreement with the ULP and CNRS
Read More
Palatin provides update on phase II trial of bremelanotide for FSAD
Read More
The Medicines Company's sNDA for expanded use of Angiomax accepted by FDA
Read More
Update on EMEA submission for Rapinyl for breakthrough cancer pain
Read More
Santhera to initiate phase III trial of SNT-MC17 under SPA with FDA
Read More
Biomira changes name to Oncothyreon
Read More
Preclinical results of VEL-0230, a dual-action cathepsin K inhibitor, reported
Read More
Positive preclinical results of the anti-varicella zoster virus agent FV-100
Read More
Basilea submits MAA to Swissmedic for oral alitretinoin for CHE
Read More
Tanabe Seiyaku and Mitsubishi Pharma merge to form Mitsubishi Tanabe Pharma
Read More
FDA approves CSL's influenza vaccine Afluria
Read More
EC expands indication of Amgen's Aranesp
Read More
Recent patents impart new therapeutic agents for cancer
Read More
Once-daily oral antihistamine Xyzal available by prescription in U.S.
Read More
New antipsoriatic agents reported by Wisconsin Alumni Research Foundation
Read More
Novel histamine H3 receptor ligands reported in recent Abbott patent
Read More